cerrar
Tagged with USA

Abhijit Zutshi – Commercial Head Global Generics & SVP…
Abhijit Zutshi, commercial head global generics & SVP marketing at Indian firm Biocon highlights the challenges inherent in the US generics…

Dan Leonard – President & CEO, National Pharmaceutical…
Dan Leonard is president & CEO of the National Pharmaceutical Council, which sponsors and participates in research on the appropriate use of…

“Drug” Companies are Missing Their Moment to Write a New…
John G. Singer examines how the ongoing coronavirus pandemic may create a new dichotomy for global healthcare - and why pharma companies still wedded…

Dan Minoiu – Partner, Mușat & Asociații, Romania
Dan Minoiu, partner at Romanian law firm Mușat & Asociații, shares his insights into the main trends shaping the healthcare environment in…

How US Generics Firms are Responding to COVID-19 Supply Chain…
AAM Interim President Jeff Francer outlines the vital role that biosimilar and generics firms will play in filling supply chain gaps during the…

First Antibiotic Discovered Using Artificial Intelligence
Artificial intelligence (AI) is increasingly being utilised in the drug discovery process, with the latest breakthrough being the development of an…

Indian Generics Companies in the US Snapshot
The US generics market stood at USD 69 billion in 2018 and is expected to grow to USD 86 billion by 2022. Made with Visme Infographic Maker…

Indian Generics in the USA: Destined for More Success?
A recent IQVIA report highlights the increasing importance of Indian firms to the USA’s burgeoning generic pharmaceuticals market. Now…

Roche’s Coronavirus Test Gets FDA Emergency Use…
Over the past few years, innovative Swiss giant Roche has combined its position as the world’s number 1 biotech company and its strength in in vitro…

Iulia Arif-Percă – Executive Director, Local American…
Iulia Arif-Percă executive director of the Local American Working Group (LAWG), shares her insights on the launched initiatives to finding new…

Chiesi Moves into Rare Diseases & the US Market
Italian mid-cap firm Chiesi is continuing its expansion in the USA market with the launch of a Boston-based subsidiary focusing on rare and ultra-rare…

US FDA New Drug Approvals 2019 Snapshot
Annual numbers of new molecular entities (NMEs) and biologics license applications (BLAs) approved by the FDA's Center for Drug Evaluation and…
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here